Y Combinator is a startup accelerator that funds early-stage companies through seed investments and a three-month, batch-based program. Founders receive mentorship, guidance on product and business strategy, and a Demo Day to present to invited investors. The program runs four times a year, creating a strong network effect among participants who can support one another and share experiences. The accelerator’s portfolio spans software, fintech, biotech, and consumer products, with notable alumni including Stripe, Airbnb, and Coinbase. Unlike many investors, Y Combinator combines a small equity stake with access to a vast alumni and investor network, monetizing returns from successful exits such as acquisitions or IPOs. Its goal is to identify high-potential ventures, help them grow, and generate meaningful financial returns for its stakeholders through exits.
Company Size
1,001-5,000
Company Stage
Pre-seed
Total Funding
$50.3B
Headquarters
San Francisco, California
Founded
2005
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Parental Leave
Fertility Treatment Support
Commuter Benefits
Molagri has raised $5.8 million in seed funding to build biopesticides that can be "updated" as pests develop resistance. Convective Capital led the round, with Superorganism, Y Combinator, Julian Capital and angels including Paul Graham taking part. Its platform, developed by Zaky Hassan and Min Jin, uses engineered non-infectious virus-like particles. Pests ingest them, and the particles deliver mRNA that makes the insect's own cells produce a toxin. Beneficial insects such as pollinators lack the targeted receptor, so are unaffected. The modular design lets Molagri swap targeting or toxin components as pests evolve. Early targets include navel orangeworm and codling moth. The money will fund hires in insect biology, virology and particle production. Field performance and regulatory treatment remain unproven.
Probably Genetic, an AI platform for diagnosing and treating genetic diseases, has raised $12 million in series A funding. Threshold led the round, with Y Combinator and existing investors taking part. Total funding now stands at $14 million. The company will use the money to grow its core business, hire staff, and enter drug discovery. It sells a physician-ordered genetic test for undiagnosed rare disease patients, with free testing through pharma partnerships or insurance-billed testing. Its platform turns symptoms, medical records, and biological data into datasets, drawn so far from 130,000 patients. It plans to add proteomic testing in 2027, paid for by pharma partners. Founded in 2018, the company is profitable. In August, it won up to $10 million from ARPA-H.
Clueso raises $10M Series A to build the agentic video platform for businesses...
Clueso, an agentic video startup founded by IIT Madras alumni, has raised $10 million in a Series A funding round. The company plans to use the money to scale its enterprise go-to-market reach, deepen its agentic layer, and expand its editing capabilities.
Emergent, an AI platform that helps non-technical founders and small business owners build production-ready web and mobile apps, raised $130 million in a Series C round. Creaegis led the round, joined by Claypond and Sentinel Global, with Khosla Ventures, SoftBank Vision Fund 2, Lightspeed, and Y Combinator also taking part. The round quintuples the company's valuation to $1.5 billion in four months, making it a unicorn a year after public launch. Users have built more than 12 million apps on the platform in the past year, and 70% had no prior coding experience. Over half of customers use it to build software critical to their businesses. "The real impact of the AI revolution will be a complete democratization of who gets to build what software," said Mukund Jha, co-founder and chief executive officer.